Patient-adapted, specific activation of HIV-1 by customized TAL effectors (TALEs), a proof of principle study
Abstract The major obstacle to cure infections with human immunodeficiency virus (HIV-1) is integrated proviral genomes, which are not eliminated by antiretroviral therapies (ART). Treatment approaches with latency-reversing agents (LRAs) aim at inducing provirus expression to tag latently-infected...
Saved in:
Published in | Virology (New York, N.Y.) Vol. 486; pp. 248 - 254 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.12.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!